Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

551 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Current State of Biotransformation Science - Industry Survey of In Vitro and In Vivo Practices, Clinical Translation, and Future Trends.
Savaryn JP, Coe K, Cerny MA, Colizza K, Moliner P, King L, Ma B, Atherton J, Auclair A, Cancilla MT, Eno M, Jurva U, Yue Q, Zhu SX, Freiberger E, Zhong G, Barlock B, Nachtigall J, Laboureur L, Pusalkar S, Guo R, Niehues M, Hauri S, Carreras ET, Maurer C, Prakash C, Jenkins GJ. Savaryn JP, et al. Among authors: atherton j. Pharm Res. 2024 Nov 4. doi: 10.1007/s11095-024-03787-y. Online ahead of print. Pharm Res. 2024. PMID: 39496990
Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.
Beebe JS, Jani JP, Knauth E, Goodwin P, Higdon C, Rossi AM, Emerson E, Finkelstein M, Floyd E, Harriman S, Atherton J, Hillerman S, Soderstrom C, Kou K, Gant T, Noe MC, Foster B, Rastinejad F, Marx MA, Schaeffer T, Whalen PM, Roberts WG. Beebe JS, et al. Among authors: atherton j. Cancer Res. 2003 Nov 1;63(21):7301-9. Cancer Res. 2003. PMID: 14612527
Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.
Roberts WG, Whalen PM, Soderstrom E, Moraski G, Lyssikatos JP, Wang HF, Cooper B, Baker DA, Savage D, Dalvie D, Atherton JA, Ralston S, Szewc R, Kath JC, Lin J, Soderstrom C, Tkalcevic G, Cohen BD, Pollack V, Barth W, Hungerford W, Ung E. Roberts WG, et al. Among authors: atherton ja. Cancer Res. 2005 Feb 1;65(3):957-66. Cancer Res. 2005. PMID: 15705896
A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif.
Kalgutkar AS, Driscoll J, Zhao SX, Walker GS, Shepard RM, Soglia JR, Atherton J, Yu L, Mutlib AE, Munchhof MJ, Reiter LA, Jones CS, Doty JL, Trevena KA, Shaffer CL, Ripp SL. Kalgutkar AS, et al. Among authors: atherton j. Chem Res Toxicol. 2007 Dec;20(12):1954-65. doi: 10.1021/tx700270r. Epub 2007 Oct 13. Chem Res Toxicol. 2007. PMID: 17935300
Characterization of HKI-272 covalent binding to human serum albumin.
Wang J, Li-Chan XX, Atherton J, Deng L, Espina R, Yu L, Horwatt P, Ross S, Lockhead S, Ahmad S, Chandrasekaran A, Oganesian A, Scatina J, Mutlib A, Talaat R. Wang J, et al. Among authors: atherton j. Drug Metab Dispos. 2010 Jul;38(7):1083-93. doi: 10.1124/dmd.110.032292. Epub 2010 Apr 16. Drug Metab Dispos. 2010. PMID: 20400660
551 results